Cardiol Therapeutics Inc. - CRDL STOCK NEWS

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) announced plans to advance CardiolRx™ into a late-stage clinical trial called MAVERIC-2. This trial will evaluate the impact of CardiolRx™ in recurrent pericarditis patients following cessation of interleukin-1 (IL-1) blocker therapy. MAVERIC-2 is expected to be initiated during Q4 at major pericardial disease centers in the United States and Europe.

The trial is designed as a randomized, double-blind, placebo-controlled Phase II/III study with approximately 110 patients. The primary clinical objective is to assess the impact of CardiolRx™ versus placebo on freedom from a new episode of recurrent pericarditis. This study is expected to run concurrently with the Company's planned Phase III program and report results ahead of the pivotal Phase III study in recurrent pericarditis.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has announced the successful exercise and closing of the over-allotment option for its public offering. Canaccord Genuity purchased an additional 1,265,625 Class A common shares at US$1.60 per share, resulting in additional gross proceeds of $2,025,000. The total offering, including the over-allotment, now comprises 9,703,125 shares for aggregate gross proceeds of US$15,525,000.

The company plans to use the net proceeds to support the clinical development of CardiolRx for treating recurrent pericarditis, as well as for general and administrative expenses, working capital, and other expenses. The offering was made pursuant to U.S. and Canadian regulatory filings, including a U.S. registration statement on Form F-10 and a Canadian short form base shelf prospectus.

Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) has successfully closed its public offering of 8,437,500 Class A common shares at US$1.60 per share, raising gross proceeds of US$13.5 million. The company plans to use the net proceeds to support the clinical development of CardiolRx for treating recurrent pericarditis, as well as for general and administrative expenses, working capital, and other expenses.

Canaccord Genuity acted as the sole bookrunner for the offering. The offering was made pursuant to a U.S. registration statement on Form F-10 and the company's existing Canadian short form base shelf prospectus. A final prospectus supplement was filed with securities commissions in Canada (except Quebec) and the SEC in the United States.

Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) has announced the pricing of its public offering of 8,437,500 Class A common shares at US$1.60 per share, aiming to raise US$13.5 million in gross proceeds. The company plans to use the funds to support the clinical development of CardiolRx for treating recurrent pericarditis, as well as for general expenses and working capital. Canaccord Genuity is acting as the sole bookrunner for the offering, which is expected to close around October 10, 2024. The offering is being made under a U.S. registration statement and Canadian short form base shelf prospectus, with a final prospectus supplement to be filed with relevant securities commissions.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has filed a preliminary prospectus supplement for a proposed public offering of Class A common shares. The supplement was filed with the SEC and SEDAR+ in connection with the company's short form base shelf prospectus. Canaccord Genuity is acting as the sole bookrunner for the offering.

The net proceeds from the offering will be used to support the clinical development of CardiolRx for the treatment of recurrent pericarditis, as well as for general and administrative expenses, working capital, and other expenses. The offering's final terms, including pricing, will be determined in the context of the market. The closing is subject to customary conditions, including listing approvals from the TSX and Nasdaq.

Interested investors can find detailed information about the offering in the supplement and base prospectus available on SEDAR+ and EDGAR.

Cardiol Therapeutics (NASDAQ: CRDL) announced the completion of target patient enrollment for its Phase II ARCHER trial, evaluating CardiolRx™ in acute myocarditis. The trial, with 100 patients from five countries, aims to assess the safety, tolerability, and impact of CardiolRx™ on myocardial recovery. Primary outcomes include measures of left ventricular function and myocardial edema/fibrosis, with topline results expected early next year. This milestone complements data from the MAvERIC Phase II study on recurrent pericarditis, to be presented in November. Acute myocarditis, a severe inflammatory heart disease, lacks FDA-approved therapies, presenting a significant opportunity for Cardiol.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has announced the completion of its MAvERIC Phase II study for recurrent pericarditis. The full clinical data will be presented at the American Heart Association Scientific Sessions 2024 on November 18, 2024. The study investigated the impact of CardiolRx™ on patients with symptomatic recurrent pericarditis. The primary endpoint data showed marked reductions in pericarditis pain and inflammation at 8 weeks. The study involved 27 adult participants across eight U.S. clinical sites and consisted of an 8-week treatment period followed by an 18-week extension period. The presentation will include additional endpoints such as freedom from pericarditis recurrence, 26-week pain scores, inflammatory marker levels, and safety outcomes.

Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) held its annual general and special meeting of shareholders on June 26, 2024. Shareholders voted in favor of all proposed management resolutions. Key resolutions included the re-election of eight directors and the appointment of BDO Canada LLP as auditors. Additionally, the unallocated awards under Cardiol's Omnibus Equity Incentive Plan were approved. The re-elected directors are David Elsley, Peter Pekos, Dr. Guillermo Torre-Amione, Colin Stott, Michael Willner, Jennifer Chao, Chris Waddick, and Teri Loxam. The voting results showed strong support, with directors receiving between 96.01% and 99.66% of the votes cast.

Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) has announced that its Annual General and Special Meeting of Shareholders will be held virtually on June 26, 2024, at 4:30 p.m. EDT. The meeting will be accessible via a live audio webcast at web.lumiagm.com/253136217. During this event, shareholders can participate and vote on various matters. Cardiol is a clinical-stage company dedicated to developing anti-inflammatory and anti-fibrotic therapies for heart disease. Further details on the AGM and participation instructions are available on Cardiol's investor website.